11C-M503
Tauopathies
University of PennsylvaniaEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Tauopathies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLORTAUCIPIR Columbia University | Phase 2 | BB |
Donanemab Eli Lilly and Company | Phase 3 | B |
NA 831 Biomed Industries, Inc. | Phase 2 | B |
Aci-35.030 AC Immune SA | Phase 1/2 | CCC |
Jaci-35.054 AC Immune SA | Phase 1/2 | CCC |
View all 14 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →